Compare GRFS & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | FOLD |
|---|---|---|
| Founded | 1940 | 2002 |
| Country | Spain | United States |
| Employees | 25247 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | N/A | 2006 |
| Metric | GRFS | FOLD |
|---|---|---|
| Price | $8.27 | $14.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $10.15 | ★ $27.25 |
| AVG Volume (30 Days) | 573.0K | ★ 2.4M |
| Earning Date | 07-28-2022 | 05-06-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.49 | $20.50 |
| Revenue Next Year | $6.42 | $18.59 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.08 | $5.66 |
| 52 Week High | $11.14 | $14.50 |
| Indicator | GRFS | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 74.18 |
| Support Level | $7.64 | $14.21 |
| Resistance Level | $8.88 | N/A |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 38.54 | 100.00 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.